**Abstract**

**Objective:** The treatment successful rate is one of the major concerns in acute phase of schizophrenia. This study aimed to evaluate the treatment successful rate and efficacy of Paliperidone ER in acute schizophrenia and schizoaffective disorder patients.

**Method:** Retrospective 12 months patients who received Paliperidone ER treatment after admitted to acute ward as first-line antipsychotic were enrolled in this study. The primary endpoint was Clinical Global Impression-Severity (CGI-S) score. Secondary endpoints included dosage distributed rate of Paliperidone ER while admission and discharged, combined medication (anticholinergics) situation, duration dates of admission. Treatment successful was defined to change CGI-S score more than 1 point. Combined other antipsychotics were not allowed. .

**Results:** 40 Patients enrolled. Treatment successful rate is 86%. Mean CGI-S score changed from 4.77 to 3.2. Admission dosage distributed rate is 9mg 39%; 12mg 33%, discharge dosage distributed rate is 9mg 28%; 12mg 44%. Anticholinergics were frequently needed to prevent EPS symptoms, but additional dosage didn't need. Average duration date of admission is 33.6 days.

**Conclusion:** In acute ward we need to control patient's symptoms in short time. We may not have too much time to try the second antipsychotic during admission. In this study we find that Paliperidone ER can offer enough successful rate when first-line use. Maybe start with optimal dosage (9\~12mg) can be more ensured highest successful treatment rate, and seems safe when higher dosage usage. We expect Paliperidone ER can effectively help patient improve during acute stage schizophrenia.
